[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-08-17-24":3},{"date":4,"filings":5,"has_more":109,"limit":110,"page":111,"total_count":112},"2026-08-17",[6,14,18,26,30,37,41,48,52,59,63,70,74,79,83,90,94,101,105],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Veerhealth Care Ltd","2026-08-17T09:00:25.026000","BSE","Posts Record-Breaking Q1 with 388% Revenue Surge","6a82807f823a3c20f30a7a40","511523","*   \u003Cb>Q1FY27 Financials:\u003C\u002Fb> Reported its highest-ever quarterly total income of \u003Cb>₹25.09 Cr\u003C\u002Fb> (up 388% YoY) and a Net Profit of \u003Cb>₹1.23 Cr\u003C\u002Fb> (up 412% YoY).\n*   \u003Cb>Major New Orders:\u003C\u002Fb> Secured significant new orders in FY27, including a \u003Cb>₹18.24 Cr\u003C\u002Fb> order from a leading Indian FMCG company and a \u003Cb>₹2.93 Cr\u003C\u002Fb> order from the USA.\n*   \u003Cb>USFDA Clearance:\u003C\u002Fb> Received USFDA clearance for its plant, enabling the export of Over-the-Counter (OTC) drug products to the USA.\n*   \u003Cb>Market Expansion:\u003C\u002Fb> Entered the African market with an order from Sudan and is in advanced talks for exports to Russia.\n*   \u003Cb>FY27 Guidance:\u003C\u002Fb> Management expects to achieve a total income of \u003Cb>₹105 Cr\u003C\u002Fb> and a Net Profit of \u003Cb>₹5-6 Cr\u003C\u002Fb> for the full fiscal year 2026-27.",{"company_name":7,"filing_date":8,"filing_source":9,"headline":15,"id":16,"stock_code":12,"summary_text":17},"Q1FY27 Profits Surge Over 400%, USFDA Clearance Secured","6a82809b3e4381ec486fc280","*   **Stellar Q1FY27 Results:** Net Profit (PAT) soared by **412.50%** YoY to ₹1.23 Crore, while Total Revenues grew **388.13%** YoY to ₹25.09 Crore.\n*   **Major USFDA Clearance:** The company received USFDA clearance for its plant, enabling the export of Drug (OTC) products to the USA.\n*   **Significant New Orders:** Secured new orders worth over ₹22 Crore in FY27, including a large domestic order of ₹18.24 Crore.\n*   **Strong Future Guidance:** Management projects Total Income to reach ₹105 crores in FY27 and ₹156 crores in FY28.",{"company_name":19,"filing_date":20,"filing_source":21,"headline":22,"id":23,"stock_code":24,"summary_text":25},"Hero MotoCorp Limited","2026-08-17T09:00:24.939000","NSE","Hero MotoCorp Appoints New Chief Strategy Officer","6a8280735ffc3b421f6fc267","HEROMOTOCO","*   **Appointment:** Mr. Srihari Mulgund has been appointed as the new **Chief Strategy Officer**, effective August 17, 2026. He will be designated as Senior Management Personnel.\n*   **Appointee Profile:** Mr. Mulgund has over 24 years of global automotive experience in engineering, product development, and strategy, with previous leadership roles at EY-Parthenon and Ricardo Strategic Consulting.\n*   **Strategic Focus:** The appointment aims to strengthen the leadership team and advance strategic initiatives, particularly in EV, battery swapping, software-defined vehicles, and hydrogen technologies.\n*   **Regulatory Filing:** The announcement was made to the NSE and BSE in compliance with SEBI's Regulation 30.",{"company_name":19,"filing_date":20,"filing_source":21,"headline":27,"id":28,"stock_code":24,"summary_text":29},"Hero MotoCorp Appoints Automotive Veteran as New Chief Strategy Officer","6a8280937132835fab79ecb4","• Mr. Srihari Mulgund has been appointed as the new **Chief Strategy Officer**, effective August 17, 2026.\n• He brings over 24 years of global automotive experience from previous leadership roles at EY-Parthenon, Ricardo Strategic Consulting, and Aisin AW.\n• As part of the Leadership Team, Mr. Mulgund will be designated as Senior Management.\n• He is expected to play a pivotal role in shaping the company's forward-looking strategic initiatives.",{"company_name":31,"filing_date":32,"filing_source":21,"headline":33,"id":34,"stock_code":35,"summary_text":36},"Schneider Electric Infrastructure Limited","2026-08-17T08:45:25.888000","Posts Record Orders Amid Profit Squeeze in Q1 FY27","6a827d012b2c739a925efa90","SCHNEIDER","*   \u003Cb>Record Orders:\u003C\u002Fb> Secured its highest-ever quarterly order intake of ₹ 915 cr, driven by major wins in Data Centers and Semiconductors.\n*   \u003Cb>Profitability Hit:\u003C\u002Fb> Profit After Tax (PAT) declined sharply by 69.8% YoY to ₹ 12.4 cr, significantly impacted by higher commodity costs and rising expenses.\n*   \u003Cb>Sales Growth:\u003C\u002Fb> Revenue from operations saw moderate growth of 4.8% YoY, reaching ₹ 651 cr for the quarter.\n*   \u003Cb>Strong Outlook:\u003C\u002Fb> The order backlog grew 32.7% YoY to a robust ₹ 2169 cr, providing healthy revenue visibility for the future.\n*   \u003Cb>Key Headwinds:\u003C\u002Fb> Management identified commodity price volatility (Copper, Aluminium, Steel) and forex fluctuations as primary risks.",{"company_name":31,"filing_date":32,"filing_source":21,"headline":38,"id":39,"stock_code":35,"summary_text":40},"Q1 FY27: Record Orders Meet Profit Headwinds","6a827d2264062855b45efa88","*   Achieved highest-ever quarterly order intake of ₹915 crore, marking a significant milestone for the company.\n*   Profit After Tax (PAT) plunged 69.8% year-over-year to ₹12.4 crore, primarily due to rising commodity costs and a time lag in passing on price hikes to customers.\n*   Sales grew moderately by 4.8% to ₹651 crore, with growth influenced by project execution timelines.\n*   The order backlog remains robust, growing 32.7% YoY to ₹2,169 crore, which provides healthy revenue visibility for future quarters.\n*   Secured strategic wins in high-growth sectors, including its largest-ever order in the semiconductor industry and key projects in data centers and renewables.",{"company_name":42,"filing_date":43,"filing_source":21,"headline":44,"id":45,"stock_code":46,"summary_text":47},"Sun Pharmaceutical Industries Limited","2026-08-17T08:45:24.950000","Sun Pharma Secures Major Win in Lipitor Antitrust Litigation","6a827cf875683df2585efab2","SUNPHARMA","*   A U.S. Court of Appeals has ruled in favor of Sun Pharma in the long-running Lipitor antitrust litigation.\n*   The court affirmed a prior summary judgment granted to the company and also upheld the denial of class certification to the plaintiffs.\n*   This decision brings the litigation \"substantially to a close,\" removing a significant legal and financial risk for the company.\n*   The development is positive for shareholders as it resolves the uncertainty and potential liability from the case.",{"company_name":42,"filing_date":43,"filing_source":21,"headline":49,"id":50,"stock_code":46,"summary_text":51},"Major Legal Victory in U.S. Lipitor Antitrust Case","6a827d175ffc3b421f6fc266","*   A U.S. Court of Appeals has affirmed a summary judgment *in its entirety in favour of the Company* in the long-standing Lipitor antitrust litigation.\n*   The ruling is a significant de-risking event, removing a major contingent liability and bringing the litigation substantially to a close.\n*   The court also affirmed the denial of class certification to the plaintiffs, marking a comprehensive win for the company.",{"company_name":53,"filing_date":54,"filing_source":21,"headline":55,"id":56,"stock_code":57,"summary_text":58},"Aurobindo Pharma Limited","2026-08-17T07:35:24.967000","USFDA Gives Green Light to Raleigh Plant, Clearing Path for New Products","6a826cad823a3c20f30a7a2a","AUROPHARMA","*   The USFDA has concluded its inspection of the Raleigh, NC plant, classifying it as \"Voluntary Action Indicated\" (VAI), a positive outcome.\n*   This positive classification means the inspection, which initially had 11 observations, is now officially closed.\n*   Crucially, this allows pending applications for new inhalers and other products from the facility to proceed through the USFDA review process.\n*   The update is a significant positive development, reducing regulatory risk and clearing the way for future growth in the US market.",{"company_name":53,"filing_date":54,"filing_source":21,"headline":60,"id":61,"stock_code":57,"summary_text":62},"US FDA Clears Path for New Products from Raleigh Plant","6a826cb17132835fab79ecb3","• The US Food and Drug Administration (USFDA) has concluded its inspection of the company's Raleigh, NC manufacturing facility.\n• The facility received a positive \"Voluntary Action Indicated\" (VAI) classification, resolving the 11 observations previously issued.\n• This allows pending applications for inhalers and other products from this plant to proceed with the FDA's review process, paving the way for potential future approvals.",{"company_name":64,"filing_date":65,"filing_source":21,"headline":66,"id":67,"stock_code":68,"summary_text":69},"Kotak Mahindra Bank Limited","2026-08-17T06:40:24.925000","Q1FY27 Update: Profit Jumps 26% & Asset Quality Strengthens","6a825fc0823a3c20f30a7a29","KOTAKBANK","*   **Strong Profitability**: Consolidated Profit After Tax (PAT) surged 26% YoY to ₹4,123 crore for Q1FY27.\n*   **Robust Growth**: Net Advances grew by a strong 15% YoY to ₹5.12 lakh crore, driven by a 20% YoY growth in the Institutional Banking segment.\n*   **Improved Asset Quality**: Asset quality saw significant improvement, with the Gross NPA ratio falling to 1.18% (from 1.48% YoY) and the Net NPA ratio down to 0.27% (from 0.34% YoY).\n*   **Solid Capital Position**: The bank maintains a robust capital adequacy with a CET-1 Ratio of 22.4% as of June 30, 2026.\n*   **Strategic Focus**: The bank continues to focus on its three pillars: key customer segments, independent product businesses, and technology\u002Fdigital transformation.",{"company_name":64,"filing_date":65,"filing_source":21,"headline":71,"id":72,"stock_code":68,"summary_text":73},"Q1FY27 Investor Update: Profit Jumps 26% YoY","6a825fdd75683df2585efab1","*   The bank filed its August 2026 Investor Presentation for Q1FY27 (quarter ended June 30, 2026).\n*   \u003Cb>Consolidated Profit After Tax (PAT):\u003C\u002Fb> Grew 26% YoY to ₹4,123 cr.\n*   \u003Cb>Loan & Deposit Growth:\u003C\u002Fb> Net Advances increased by 15% YoY to ₹512,249 cr, and Deposits grew by 12% YoY to ₹572,820 cr.\n*   \u003Cb>Asset Quality & Capital:\u003C\u002Fb> Net NPA remains stable at 0.27%. The CET-I Ratio is robust at 22.4%.\n*   \u003Cb>Segment Performance:\u003C\u002Fb> Institutional Banking was the top-performing segment, with loan book growth of 20% YoY, driven by a strong SME book.\n*   \u003Cb>Strategic Focus:\u003C\u002Fb> Management reiterated its focus on HNI clients, Core India (Kotak811), and the SME segment, underpinned by technology and AI investments.",{"company_name":64,"filing_date":75,"filing_source":21,"headline":76,"id":77,"stock_code":68,"summary_text":78},"2026-08-17T06:30:24.899000","Investor Update: PAT Jumps 26% in Q1FY27","6a825d667132835fab79ec98","- Consolidated Profit After Tax (PAT) surged 26% YoY to ₹ 4,123 cr for Q1FY27.\n- Net Advances grew 15% YoY to ₹ 512,249 cr, driven by strong performance in SME (↑20%) and Corporate Banking (↑15%).\n- Asset quality strengthened, with Gross NPA improving to 1.18% and Net NPA to 0.27%.\n- The bank maintains a robust Capital Adequacy Ratio (CAR) of 22.8%.\n- Digital customer acquisition remains a key focus, with the Kotak811 platform's savings accounts growing 32% YoY.",{"company_name":64,"filing_date":75,"filing_source":21,"headline":80,"id":81,"stock_code":68,"summary_text":82},"Q1FY27 Profit Jumps 26% on Strong Loan Growth & Healthy Asset Quality","6a825d9175683df2585efab0","*   Consolidated Profit After Tax (PAT) surged 26% YoY to ₹4,123 Crores for the quarter ended June 30, 2026.\n*   Net Advances grew 15% YoY to ₹5.12 lakh crores, driven by strong performance in Institutional Banking (20% YoY growth).\n*   Asset quality remains robust with Net NPA at a low 0.27% and a strong Provision Coverage Ratio of 78%.\n*   The bank maintains a very strong capital position with a CET-I Ratio of 22.4%.\n*   Management holds a constructive outlook on India's economy, projecting ~7% GDP growth and ~5% inflation for FY27.",{"company_name":84,"filing_date":85,"filing_source":9,"headline":86,"id":87,"stock_code":88,"summary_text":89},"Kotak Mahindra Bank Ltd","2026-08-17T06:15:25.004000","Q1 FY27 PAT Jumps 26% YoY to ₹4,123 Cr","6a825a013e4381ec486fc27f","500247","*   **Consolidated PAT:** Grew **26% YoY** to **₹4,123 cr** for Q1 FY27.\n*   **Net Interest Income (NII):** Increased by 9% YoY to ₹7,928 cr.\n*   **Advances & Deposits:** Net Advances grew **15% YoY** to ₹5.12 lakh cr; Deposits up **12% YoY** to ₹5.72 lakh cr.\n*   **Asset Quality:** Stable with Net NPA at **0.27%** and a Provision Coverage Ratio (PCR) of 78%.\n*   **Capital Adequacy:** Robust CET-I ratio at **22.4%**.\n*   **Key Ratios (Q1 FY27):** Return on Assets (ROA) at 2.14% and Return on Equity (ROE) at 11.98%.\n*   **Digital Acquisition:** Kotak811 continues strong momentum with a monthly customer acquisition run rate of **298K**.",{"company_name":84,"filing_date":85,"filing_source":9,"headline":91,"id":92,"stock_code":88,"summary_text":93},"Q1FY27 Update: Consolidated Profit Jumps 26% YoY to ₹4,123 Cr","6a825a105ffc3b421f6fc265","• \u003Cb>Strong Profitability:\u003C\u002Fb> Consolidated Profit After Tax (PAT) for Q1FY27 grew 26% YoY to ₹4,123 crore, driven by a 45% reduction in provisions.\n• \u003Cb>Loan Book Growth:\u003C\u002Fb> Total advances increased by 15% YoY to ₹5.27 lakh crore, led by a 20% rise in Institutional Banking.\n• \u003Cb>Improved Asset Quality:\u003C\u002Fb> Gross NPA ratio improved significantly to 1.18% from 1.48% YoY, and Net NPA fell to 0.27% from 0.34% YoY.\n• \u003Cb>Robust Capitalization:\u003C\u002Fb> The bank's CET-I Ratio remains strong at 22.4% as of June 30, 2026.\n• \u003Cb>CASA Ratio:\u003C\u002Fb> The CASA (Current Account Savings Account) ratio moderated slightly to 40.3% from 40.9% a year ago.",{"company_name":95,"filing_date":96,"filing_source":21,"headline":97,"id":98,"stock_code":99,"summary_text":100},"Yes Bank Limited","2026-08-17T02:05:24.992000","Revised Investor Presentation Highlights Strong Q1 FY27 Performance & Strategic Growth","6a821f75823a3c20f30a7a28","YESBANK","*   The filing is a revised Debt Investor Presentation for Q1 FY27 (quarter ended June 30, 2026), correcting a minor error in a previous version.\n*   **Q1 FY27 Financial Highlights:** Net Profit of ₹11 Bn, robust asset quality with Net NPA at 0.2%, and a strong CET-1 Ratio of 14.0%.\n*   **Strategic Shareholding:** Sumitomo Mitsui Banking Corporation (SMBC) has become the bank's largest shareholder with a 24.9% stake.\n*   **Credit Rating Upgrades:** The bank received significant rating upgrades in 2026 from multiple agencies, including Moody's (to Ba1), CRISIL (to AA+), and an inaugural rating from S&P (BB+).\n*   **Digital Leadership:** The bank continues its dominance in digital payments, processing approximately 1 in 3 digital transactions in India.",{"company_name":95,"filing_date":96,"filing_source":21,"headline":102,"id":103,"stock_code":99,"summary_text":104},"Strong Q1 FY27 Performance & Multiple Credit Rating Upgrades","6a821f7e7132835fab79ec97","• \u003Cb>Q1 FY27 Highlights:\u003C\u002Fb> Net Profit of INR 11 Bn, annualized Return on Assets (RoA) at 0.9%, and Net Interest Margin (NIM) at 2.7%.\n• \u003Cb>Strong Asset Quality:\u003C\u002Fb> Gross NPA stable at 1.3% and Net NPA at a low 0.2%, with a Provision Coverage Ratio of 81.7%.\n• \u003Cb>Robust Capital & Liquidity:\u003C\u002Fb> Capital Adequacy Ratio (CRAR) at 15.1% and a healthy Liquidity Coverage Ratio (LCR) of 138.2%.\n• \u003Cb>Major Credit Rating Upgrades:\u003C\u002Fb> Received significant upgrades in 2026 from Moody's (to Ba1), CRISIL (to AA+), India Ratings (to AA+), and others, reflecting an enhanced credit profile.\n• \u003Cb>Strategic Shareholding:\u003C\u002Fb> Key backing from Sumitomo Mitsui Banking Corporation (SMBC) with a 24.9% stake and State Bank of India (SBI) with a 10.8% stake.",{"company_name":95,"filing_date":96,"filing_source":21,"headline":106,"id":107,"stock_code":99,"summary_text":108},"Revised Investor Presentation: Q1FY27 Highlights","6a821fafc55eb4adfb79ec7e","• The company filed a revised Debt Investor Presentation to correct a typographical error from a previous submission. The presentation covers performance as of June 30, 2026.\n• \u003Cb>Q1FY27 Performance:\u003C\u002Fb> Reported a Net Profit of ₹11 Bn and Net Interest Income of ₹28 Bn. Annualized Return on Assets (RoA) stood at 0.9%.\n• \u003Cb>Strong Asset Quality:\u003C\u002Fb> Gross NPA improved to 1.3% and Net NPA was stable at 0.2%. The Provision Coverage Ratio (PCR) is strong at 81.7%.\n• \u003Cb>Major Credit Rating Upgrades:\u003C\u002Fb> Received significant upgrades in 2026 from Moody's (to Ba1), CRISIL (to AA+), and India Ratings (to AA+), signaling enhanced creditworthiness.\n• \u003Cb>Strategic Shareholding:\u003C\u002Fb> Sumitomo Mitsui Banking Corporation (SMBC) is now the largest shareholder with a 24.9% stake.\n• \u003Cb>Digital Leadership:\u003C\u002Fb> The bank maintains its dominance in digital payments, processing approximately 1 in 3 digital transactions in India.",false,100,24,2319]